|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Chemotherapy does not affect the TP53 mutational status in HGSC.
|
31471396 |
2020 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used integrated molecular characterization of oviductal HGSCs arising in the context of Brca1, Trp53, Rb1, and Nf1 (BPRN) inactivation to determine whether the mouse tumors recapitulate human HGSCs across multiple domains of molecular features.
|
31806642 |
2020 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In one of the four women with co-existing ovarian HGSC and tubal precursor lesion we found non-identical TP53 mutations and a lack of common mutations shared between her precursor lesion and carcinoma.
|
30560554 |
2019 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent work predominantly carried out in tubo-ovarian high-grade serous carcinoma has revealed 4 main patterns of p53 staining (normal/wild-type, complete absence, overexpression, and cytoplasmic); the latter 3 patterns are variably termed abnormal/aberrant/mutation-type and are strongly predictive of an underlying TP53 mutation.
|
29517499 |
2019 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Novel TP53 in-frame deletion mutations c.719_727delGTTCCTGCA (p53 p.Ser240_Cys242del) and c.634_642delTTTCGACAT (p53 p.F212_H214del) were detected in a single case of HGSC each.
|
31177126 |
2019 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Targeted next-generation sequencing confirmed the presence of TP53 mutations in fimbrial brushings from HGSC, but not in benign samples, and demonstrated concordance with the immunostaining pattern.
|
30861338 |
2019 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sequencing was successful in 3 of the 4 cases, and an identical Tp53 mutation was detected in the HGSC and bilateral STINs in 2 of these 3 cases.One STIN was morphologically a STIL.
|
29901519 |
2019 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Two deleterious somatic mutations in TP53 and BRCA2 genes were shared between retroperitoneal HGSC and STIC.
|
30744657 |
2019 |
|
High grade serous carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Consistent with previous studies, abnormal expression of TP53 (0 or ≥75% positive expression) was observed in 87.6% of HGSC and 13.3% of LGSC samples.
|
29620196 |
2018 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Together, our findings illustrate how TP53 mutations in HGSC subvert a normal regulatory pathway into a driver of tumor progression.
|
29379162 |
2018 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Because the putative precursors of the other p53 immunophenotypical HGSC are not proposed, we presume γ-H2AX-expressing cells without p53 overexpression may be a potent candidate of null-type TP53-mutated tubal cells, which are named "γ-H2AX responsive foci."
|
29703236 |
2018 |
|
High grade serous carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Brca1, Trp53 and Pten inactivation in the oviduct also results in STICs and HGSCs, and is associated with diffuse epithelial hyperplasia and mucinous metaplasia, which are not observed in mice with intact Pten.
|
28608929 |
2017 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry (IHC) was carried out for p53 and WT1 on paired omental HGSC samples pre-chemotherapy and post-chemotherapy. p53 IHC was recorded as normal (wild-type) or abnormal (mutation-type), and was further classified as overexpression, complete absence, or cytoplasmic.
|
28570008 |
2017 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TP53 mutation is almost invariably present in HGSC, and p53 immunostaining can be used as a surrogate marker of TP53 mutation.
|
29187446 |
2017 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we have used one ID8 Trp53 <sup>-/-</sup> clone to generate further mutants, with additional mutations in Brca1, Pten and Nf1, all of which are frequently mutated or deleted in HGSC.
|
29203787 |
2017 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
|
26166714 |
2016 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, 79% of tumors were classified as high-grade serous carcinoma (n=138), and the most common mutations in high-grade serous carcinomas were TP53 (94%), BRCA1 (25%), BRCA2 (11%), and ATM (7%).
|
27150160 |
2016 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
High-grade serous carcinoma is associated with TP53 mutations, whereas low-grade serous carcinomas are associated with BRAF and KRAS mutations.
|
26892153 |
2016 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Knockdown of p53 in immortalized FTE cells and in four HGSC-derived cell lines expressing different missense p53 mutations did not affect STMN1 protein levels.
|
26206555 |
2015 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Ovulation is the strongest risk factor for ovarian high-grade serous carcinoma (HGSC) that largely originates from the fallopian tube fimbriae and always carries loss-of-function mutations of TP53 in both early and late lesions.
|
26363031 |
2015 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We demonstrate that targeted NGS can identify genetic alterations in minute lesions, such as TICs, and confirm TP53 mutations as early driving events for HGSC.
|
26181193 |
2015 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemistry for IMP3 and p53 was performed and evaluated in 48 HGSCs with STIC, 62 HGSCs without STIC, and 60 benign cases as negative controls.
|
25038792 |
2014 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
BRCA1 and BRCA2 mutations correlate with TP53 abnormalities and presence of immune cell infiltrates in ovarian high-grade serous carcinoma.
|
22282309 |
2012 |
|
High grade serous carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the above findings support the clonal relationship of STIC and pelvic HGSC and demonstrate the utility of p53 immunostaining as a surrogate for TP53 mutation in the histological diagnosis of STIC.
|
21990067 |
2012 |
|
High grade serous carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary.
|
20229506 |
2010 |